Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: Pfizer’s COVID transition; Lilly ramps up Mounjaro on strong demand; Pfizer’s R&D head reflects on pandemic experience; parsing Novartis’s Q3; and China’s progress with mRNA vaccines.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 4 November 2022, including: Pfizer Inc.’s COVID transition; Eli Lilly and Company ramps up Mounjaro on strong demand; Pfizer’s R&D head reflects on pandemic experience; parsing Novartis AG’s Q3; and China’s progress with mRNA vaccines.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Pfizer Plans For COVID Transition And RSV Vaccine Launch" - Scrip, 1 Nov, 2022.)
(Also see "Lilly Preparing For Increasing Mounjaro Demand On Top Of Solid Launch" - Scrip, 1 Nov, 2022.)
(Also see "Pfizer R&D Chief Mikael Dolsten Reflects On The COVID-19 Pandemic Experience" - Scrip, 1 Nov, 2022.)
(Also see "Stock Watch: Why Novartis’s Q3 Misses Matter" - Scrip, 1 Nov, 2022.)
(Also see "China mRNA COVID Vaccines Progress As Shanghai Rolls Out First Inhaled Shot" - Scrip, 28 Oct, 2022.)